 STOCKHOLM, SWEDEN June 17, 2021. Karolinska Development AB Nasdaq Stockholm: KDEV announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 12 study evaluating the efficacy of the companys candidate drug eprenetapopt in combination with venteoclax and azacitidine in patients treated for TP53 mutated acute myeloid leukemia, AML. The results show that the primary efficacy endpoint of complete remission was reached in 37 of patients. 